Cytokines and anti-cytokine biologicals in autoimmunity: Present and future

Cytokine and Growth Factor Reviews

Volumn 13, Issue 4-5, 2002, Pages 299-313

  Andreakos, Evangelos T ^a   Foxwell, Brian M ^a   Brennan, Fionula M ^a   Maini, Ravinder N ^a   Feldmann, Marc ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmunity; Cytokine; NF B; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; BETA1A INTERFERON; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERFERON BETA SERINE; LENERCEPT; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DRUG EFFICACY; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CLINICAL TRIALS; CYTOKINES; DOUBLE-BLIND METHOD; FORECASTING; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MATRIX METALLOPROTEINASES; MICE; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SELF TOLERANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036695186     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(02)00018-7     Document Type: Review

References (146)

1. Oppenheim JJ, Feldmann M, editors. A compedium of cytokines and other mediators of host defense. Cytokine Reference, vol. I (ligands). New York: Academic Press, 2001.
2. Ermann J, Fathman CG. Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2001;2(9):759-61.
3. Wanstrat A, Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2001;2(9):802-9.
4. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001;2(9):777-80.
5. Silman AJ, MacGregor AJ, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nation-wide study. Br J Rheumatol 1993;32(10):903-7.
6. Feldmann M. Pathogenesis of arthritis: recent research progress. Nat Immunol 2001;2(9):771-3.
7. Owens T, Wekerle H, Antel J. Genetic models for CNS inflammation. Nat Med 2001;7(2):161-6.
8. Falcone M, Sarvetnick N. Cytokines that regulate autoimmune responses. Curr Opin Immunol 1999;11(6):670-6.
9. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
10. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34(9):1125-32.
11. Wood NC, Dickens E, Symons JA, Duff GW. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin Immunol Immunopathol 1992;62(3):295-300.
12. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989;2(Suppl):177-86.
13. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
14. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2(8657):244-7.
15. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983;306(5941):378-80.
16. Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin 1: purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 1985;162(4):1208-22.
17. Schindler R, Ghezzi P, Dinarello CA. IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J Immunol 1990;144(6):2216-22.
18. Chantry D, Turner M, Brennan F, Kingsbury A, Feldmann M. Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. Cytokine 1990;2(1):60-7.
19. Burchett SK, Weaver WM, Westall JA, Larsen A, Kronheim S, Wilson CB. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol 1988;140(10):3473-81.
20. Chantry D, Winearls CG, Maini RN, Feldmann M. Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol 1989;19(1):189-92.
21. Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Networks 1993;4(1):15-23.
22. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of pro-inflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Networks 1995;6(4):225-30.
23. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colonystimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 1991;21(10):2575-9.
24. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, Kaushansky K, Firestein GS. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol 1991;146(10):3365-71.
25. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992;89(16):7375-9.
26. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89(20):9784-8.
27. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77(4):510-4.
28. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151(11):6602-7.
29. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10(13):4025-31.
30. Probert L, Plows D, Kontogeorgos G, Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995;25(6):1794-7.
31. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989;170(5):1627-33.
32. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179(5):1517-27.
33. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994;24(11):2699-705.
34. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174(5):1209-20.
35. Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998;41(8):1388-97.
36. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35(10):1160-9.
37. Roux-Lombard P, Modoux C, Vischer T, Grassi J, Dayer JM. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells. J Rheumatol 1992;19(4):517-23.
38. Firestein GS, Berger AE, Tracey DE, et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 1992;149(3):1054-62.
39. Deleuran BW, Chu CQ, Field M, et al. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage-pannus junction in rheumatoid arthritis. Br J Rheumatol 1992;31(12):801-9.
40. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kappa B in human inflamed synovial tissue. Arthritis Rheum 1996;39(4):583-91.
41. Sioud M, Mellbye O, Forre O. Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin Exp Rheumatol 1998;16(2):125-34.
42. Elenkov IJ, Wilder RL, Bakalov VK, et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 2001;86(10):4933-8.
43. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992;102(5):1620-7.
44. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112(4):1169-78.
45. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115(1):182-205.
46. Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43(2):203-9.
47. Autschbach F, Braunstein J, Helmke B, et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol 1998;153(1):121-30.
48. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995;108(5):1434-44.
49. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109(1):129-35.
50. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117(4):761-9.
51. Grubeck-Loebenstein B, Buchan G, Chantry D, et al. Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. Clin Exp Immunol 1989;77(3):324-30.
52. Grubeck-Loebenstein B. The role of cytokines in thyroid health and disease. In: Brennan FM, Feldmann M, editors. Cytokines in autoimmunity. London: R.G. Landes Company, 1996. p. 101-20.
53. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocrinol Rev 1994;15(6):788-830.
54. Skopouli FN, Moutsopoulos HM. Cytokines in sjogren's syndrome. In: Brennan FM, Feldmann M, editors. Cytokines in autoimmunity. London: R.G. Landes Company, 1996. p. 121-36.
55. Smolen JS, Graninger WB, Studnicka-Benke A, Steiner G. Cytokines in systemic lupus erythematosus. In: Brennan FM, Feldmann M, editors. Cytokines in autoimmunity. London: R.G. Landes Company, 1996. p. 137-52.
56. Theofilopoulos AN, Lawson BR. Tumour necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 1999;58(Suppl 1):149-55.
57. Baker D, Steinmann L, Gijbels K. Cytokines in multiple sclerosis. In: Brennan FM, Feldmann M, editors. Cytokines in autoimmunity. London: R.G. Landes Company, 1996. p. 77-100.
58. Brennan FM, Feldmann M. Cytokines in autoimmunity. London: R.G. Landes Company, 1996.
59. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30(16):1443-53.
60. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36(12):1681-90.
61. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344(8930):1125-7.
62. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 1999;354(9194):1932-9.
63. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343(22):1594-602.
64. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93.
65. Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody. Ann Rheum Dis 2000;59(Suppl 1):i44-5.
66. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38(2):151-60.
67. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337(3):141-7.
68. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor-Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9.
69. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Ann Intern Med 1999;130(6):478-86.
70. Davis MW, Feige U, Bendele AM, Martin SW, Edwards III CK. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis 2000;59(Suppl 1):i41-3.
71. Sander O, Rau R, van Riel P, et al. Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a European Phase II trial. Arthritis Rheum 1996;39(Suppl):S243.
72. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41(12):2196-204.
73. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43(5):1001-9.
74. Watt I, Cobby M. Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment. Semin Arthritis Rheum (Suppl 2) 2001;30(5):21-5.
75. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJ, Mundy GR. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989;125(3):1142-50.
76. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000;57(10):1457-70.
77. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20(2):259-62.
78. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanised anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998;20(1/2):247-59.
79. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short-term cellular and molecular effects. J Immunol 1996;156(4):1646-53.
80. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41(7):1258-65.
81. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43(1):38-47.
82. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163(3):1521-8.
83. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39(7):1077-81.
84. Ballara S, Taylor PC, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001;44(9):2055-64.
85. Davis D, Charles PJ, Potter A, Feldmann M, Maini RN, Elliott MJ. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 1997;36(9):950-6.
86. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35.
87. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116(5):1029-34.
88. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116(1):22-8.
89. Rutgeerts P, D'Haens G, van Deventer SJ. Retreatment with anti-TNFa chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease [abstr.]. Gastroenterology 1997;112:a1078.
90. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18):1398-405.
91. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000;356(9244):1821-2.
92. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59(6):428-33.
93. Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43(6):1346-52.
94. Van ben Bosch F, Beaten D, Kruithof F, De Keyser F, Mielants H, Veys EM. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor a. Ann Rheum Dis 2001;60(Suppl):iii33-6.
95. Baeten D, Kruithof E, Van den Bosch F, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44(1):186-95.
96. Gorman JD, Sack KE, Davis JC. Etanercept in the treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled study [abstr.]. Arthritis Rheum 2000;43(Suppl):S403.
97. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342(11):763-9.
98. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9227):385-90.
99. Stone J, Uhlfelder M, Hellmann D, Crook S, Bedocs N, Hoffman G. Etanercept in Wegener's granulomatosis: a 6 months open-label trial evaluate safety [abstr.]. Arhtritis Rheum 2000;43(Suppl):S404.
100. Weinblatt ME, Maier AL, Overmann SS, Mease PJ, Fraser PA, Gravallese EM. Etanercept in Still's disease in the adult [abstr.]. Arhtritis Rheum 2000;43(Suppl):S391.
101. Hengstman G, van den Hoogen F, ven Engelen B, et al. Anti-TNF blockade with infliximab (Remicade®) in polymyositis and dermatomyositis [abstr.]. Arhtritis Rheum 2000;43(Suppl):S193.
102. Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: a pilot study [abstr.]. Arhtritis Rheum 2000;43(Suppl):S392.
103. Anonymous. TNF neutralization in MS: results of a randomised, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1999;53(3):457-65.
104. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47(6):1531-4.
105. Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signalling. J Exp Med 1997;185(9):1573-84.
106. Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cel receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94(2):749-60.
107. Maini RN, Paulus H, Breedveld FC, et al. The rhuIL-10 in subjects with active rheumatoid arthritis (RA): a Phase I and cytokine response study [abstr.]. Arhtritis Rheum 1997;40:S224.
108. Moreland LW, Chase W, Fife R, et al. Phase I/II study evaluating the safety and potential efficacy of recombinant interleukin-11 in patients with refractory rheumatoid arthritis. Arthritis Rheum 1999;42(Suppl):224.
109. Moreland L, Gugliotti R, King K, et al. Results of a Phase I/II randomised, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 2001;3(4):247-52.
110. Asadullah K, Docke WD, Ebeling M, et al. Interleukin 10 treatment of psoriasis: clinical results of a Phase II trial. Arch Dermatol 1999;135(2):187-92.
111. Asadullah K, Docke WD, Ebeling M, et al. Interleukin 10 treatment of psoriasis: clinical results of a Phase II trial. Arch Dermatol 1999;135(2):187-92.
112. McInnes IB, Illei GG, Danning CL, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001;167(7):4075-82.
113. Anonymous. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61.
114. Anonymous. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1995;45(7):1277-85.
115. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomised, double-blind placebo-controlled trial. Neurology 1993;43(4):662-7.
116. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37(5):611-9.
117. Anonymous. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Lancet 1998;352:1491-7.
118. Arnason BG, Dayal A, Qu ZX, Jensen MA, Gene K, Reder AT. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol 1996;18(1):125-48.
119. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39(3):285-94.
120. Anonymous. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Lancet 1998;352:1498-1504.
121. Li DK, Zhao GJ, Paty DW. Randomised controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001;56(11):1505-13.
122. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41(9):1552-63.
123. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91(7):2762-6.
124. Zeidler HK, Kvien TK, Hannonen P, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998;37(8):874-82.
125. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomised controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43(3):495-505.
126. Feldmann M, Miotla J, Paleolog E, et al. Future prospects for anti-cytokine treatment. Ann Rheum Dis 2000;59(Suppl 1):i119-22.
127. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralising agent. N Engl J Med 2001;345(15):1098-104.
128. Foxwell B, Browne K, Bondeson J, et al. Efficient adenoviral infection with I-kappa B alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappa B dependent. Proc Natl Acad Sci USA 1998;95(14):8211-5.
129. Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-kappa B inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA 1999;96(10):5668-73.
130. Bondeson J, Browne KA, Brennan FM, Foxwell BM, Feldmann M. Selective regulation of cytokine induction by adenoviral gene transfer of I-kappa B alpha into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, pro-inflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappa B independent. J Immunol 1999;162(5):2939-45.
131. Knauper V, Cowell S, Smith B, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997;272(12):7608-16.
132. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6(4):121-5.
133. Cowell S, Knauper V, Stewart ML, et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J 1998;331(Pt 2):453-8.
134. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-kappa B activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998;95(23):13859-64.
135. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappa B in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998;95(26):15671-6.
136. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-kappa B signal transduction pathway. Oncogene 1999;18(49):6896-909.
137. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97(17):9561-6.
138. Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell BM. NF-kappa B-inducing kinase is dispensable for activation of NF-kappa B in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappa B in primary human fibroblasts. J Immunol 2001;167(10):5895-903.
139. Conron M, Andreakos E, Pantelidis P, et al. Nuclear factor-KB activation in alveolar macrophages requires IκB kinase β, but not nuclear factor-κB inducing kinase. Am J Respir Crit Care Med 2002;165(7):996-1004.
140. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 1997;17(11):6274-82.
141. Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BM, Brennan FM. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 1998;160(2):920-8.
142. Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. J Biol Chem 2001;276(9):6666-74.
143. Dean JL, Brook M, Clark AR, Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999;274(1):264-9.
144. Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett 1998;439(1/2):75-80.
145. McLay LM, Halley F, Souness JE, et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem 2001;9(2):537-54.
146. Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108(1):73-81.